Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressing ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly (LLY) announced disappointing preliminary sales numbers, lowering its investor guidance for Q4. Meanwhile, Pfizer announced that a study evaluating a bladder cancer drug met a critical ...

Earnings Report 5.284 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.894 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.682 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.